Source comparison
Tesamorelin + Ipamorelin: Blood Work Comparison
Serum IGF-1 80–150 ng/mL (age-dependent) 150–280 ng/mL (+50–150 from baseline) Primary endpoint. Confirms pituitary GH response Fasting Glucose 70–99 mg/dL Stable or reduced (<90 mg/dL) Rising glucose suggests excessive dose or insulin resistance Fasting Insul
This comparison does not assign a generated winner or score.
- Serum IGF-1
- 80–150 ng/mL (age-dependent)
- 150–280 ng/mL (+50–150 from baseline)
- Primary endpoint. Confirms pituitary GH response
- Fasting Glucose
- 70–99 mg/dL
- Stable or reduced (<90 mg/dL)
- Rising glucose suggests excessive dose or insulin resistance
- Fasting Insulin
- 2–12 µIU/mL
- Reduced (<10 µIU/mL)
- Elevated insulin (>15) = dose too high for metabolic state
- Triglycerides
- 50–200 mg/dL
- Reduced 20–40% from baseline
- Confirms adipose mobilization. Absent change = non-response
- HDL Cholesterol
- 40–60 mg/dL
- Elevated 5–10 mg/dL
- GH-mediated lipolysis raises HDL; unchanged HDL = underdosing
- AST/ALT (Liver Enzymes)
- <40 U/L
- Transient rise <1.5× ULN acceptable
- Elevations >1.5× ULN require dose reduction
- Hemoglobin A1c
- 4.5–5.6%
- Stable or reduced (<5.4%)
- Rising A1c despite normal fasting glucose = impaired postprandial control
- Professional Assessment
- Establish numeric baseline for dose titration
- Dose-response confirmed if IGF-1 rises 50+ ng/mL with stable glucose and reduced triglycerides
- Labs guide continuation, dose adjustment, or discontinuation. Subjective assessment alone misses metabolic dysfunction